SION

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON SIONNA THERAPEUTICS, INC. (SION), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.What Hap.

Sionna Therapeutics shares plunged roughly 90% in a single trading session after the SION-719 Phase 2a readout -- erasing most of the Company's equity value. Levi & Korsinsky is investigating potential securities law violations on behalf of SION investors. Sionna Therapeutics shares plunged roughly 90% in a single trading session after the SION-719 Phase 2a readout -- erasing most of the Company's equity value. Levi & Korsinsky is investigating potential securities law violations on behalf of SION investors.

LOS ANGELES--(BUSINESS WIRE)---- $SION--SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law.

SAN DIEGO, Aug. 16, 2026 (GLOBE NEWSWIRE) -- The law firm of  Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Sionna Therapeutics, Inc. (NASDAQ: SION). If you have information that could assist in the Sionna Therapeutics investigation or if you are a Sionna Therapeutics investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-sionna-therapeutics-inc-investigation-sion.html You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at info@rgrdlaw.com.

NEW YORK--(BUSINESS WIRE)--Roughly 90% of Sionna Therapeutics (SION) market value was erased after the Company released Phase 2a PreciSION CF results for SION-719, representing a decline of approximately $40 per share from the stock's recent trading levels. If you held SION shares and suffered a loss, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. The impact on shareho.

SAN DIEGO, Aug. 12, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Sionna Therapeutics, Inc. (NASDAQ: SION).  If you have information that could assist in the Sionna Therapeutics investigation or if you are a Sionna Therapeutics investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-sionna-therapeutics-inc-investigation-sion.html You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at info@rgrdlaw.com.

Sionna Therapeutics NASDAQ: SION said its PreciSION CF Phase 2a proof-of-concept study of SION-719 added to Trikafta did not meet its key activity endpoint, prompting the company to discontinue development of SION-719 as an add-on to standard of care for cystic fibrosis.

The biotech says its cystic fibrosis drug candidate missed the mark in a Phase 2a trial, though the news could be a boon to shares of Vertex Pharmaceuticals.

Sionna Therapeutics, Inc. (SION) Discusses Clinical Trial Results and Discontinuation of 719 Program in Cystic Fibrosis Transcript

San Diego, California--(Newsfile Corp. - August 10, 2026) - Johnson Fistel, PLLP, a leading stockholder rights law firm, is investigating potential violations of the federal securities laws involving Sionna Therapeutics, Inc. (NASDAQ: SION). Click here to join the investigation.